256 related articles for article (PubMed ID: 33041005)
1. NLRP3 is dispensable for d-galactosamine/lipopolysaccharide-induced acute liver failure.
Zhang W; Tao SS; Wang T; Li YT; Chen H; Zhan YQ; Yu M; Ge CH; Li CY; Ren GM; Yin RH; Yang XM
Biochem Biophys Res Commun; 2020 Dec; 533(4):1184-1190. PubMed ID: 33041005
[TBL] [Abstract][Full Text] [Related]
2. NLRP3 inflammasome activation in D-galactosamine and lipopolysaccharide-induced acute liver failure: role of heme oxygenase-1.
Kim SJ; Lee SM
Free Radic Biol Med; 2013 Dec; 65():997-1004. PubMed ID: 23994575
[TBL] [Abstract][Full Text] [Related]
3. Biochanin A protects lipopolysaccharide/D-galactosamine-induced acute liver injury in mice by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation.
Liu X; Wang T; Liu X; Cai L; Qi J; Zhang P; Li Y
Int Immunopharmacol; 2016 Sep; 38():324-31. PubMed ID: 27344638
[TBL] [Abstract][Full Text] [Related]
4. Genipin protects d-galactosamine and lipopolysaccharide-induced hepatic injury through suppression of the necroptosis-mediated inflammasome signaling.
Seo MJ; Hong JM; Kim SJ; Lee SM
Eur J Pharmacol; 2017 Oct; 812():128-137. PubMed ID: 28709622
[TBL] [Abstract][Full Text] [Related]
5. Isoliquiritigenin alleviates LPS/ D-GalN-induced acute liver failure by activating the PGC-1α/ Nrf2 pathway to reduce oxidative stress and inflammatory response.
Wang L; Wang X; Kong L; Wang S; Huang K; Wu J; Wang C; Sun H; Liu K; Meng Q
Int Immunopharmacol; 2021 Nov; 100():108159. PubMed ID: 34555641
[TBL] [Abstract][Full Text] [Related]
6. Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3.
Xia Y; Wang P; Yan N; Gonzalez FJ; Yan T
Cell Death Dis; 2021 Feb; 12(2):174. PubMed ID: 33574236
[TBL] [Abstract][Full Text] [Related]
7. Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation.
Pan CW; Pan ZZ; Hu JJ; Chen WL; Zhou GY; Lin W; Jin LX; Xu CL
Eur J Pharmacol; 2016 Jan; 770():85-91. PubMed ID: 26668000
[TBL] [Abstract][Full Text] [Related]
8. Daphnetin alleviates lipopolysaccharide/d-galactosamine-induced acute liver failure via the inhibition of NLRP3, MAPK and NF-κB, and the induction of autophagy.
Lv H; Fan X; Wang L; Feng H; Ci X
Int J Biol Macromol; 2018 Nov; 119():240-248. PubMed ID: 30031824
[TBL] [Abstract][Full Text] [Related]
9. Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice.
Pourcet B; Zecchin M; Ferri L; Beauchamp J; Sitaula S; Billon C; Delhaye S; Vanhoutte J; Mayeuf-Louchart A; Thorel Q; Haas JT; Eeckhoute J; Dombrowicz D; Duhem C; Boulinguiez A; Lancel S; Sebti Y; Burris TP; Staels B; Duez HM
Gastroenterology; 2018 Apr; 154(5):1449-1464.e20. PubMed ID: 29277561
[TBL] [Abstract][Full Text] [Related]
10. Endotoxin tolerance ameliorates lipopolysaccharide/D-galactosamine-induced acute liver failure by negative regulation of the NF-κB/NLRP3 and activation of Nrf2/HO-1 via Sitr1.
Shi H; Xie X; Zheng S; Chen H; Liu C; Li S; Lu M
Int Immunopharmacol; 2024 May; 132():111994. PubMed ID: 38581992
[TBL] [Abstract][Full Text] [Related]
11. Propofol attenuates inflammatory response and apoptosis to protect d-galactosamine/lipopolysaccharide induced acute liver injury via regulating TLR4/NF-κB/NLRP3 pathway.
Zhang Z; Tian L; Jiang K
Int Immunopharmacol; 2019 Dec; 77():105974. PubMed ID: 31735662
[TBL] [Abstract][Full Text] [Related]
12. The LPS/D-Galactosamine-Induced Fulminant Hepatitis Model to Assess the Role of Ligand-Activated Nuclear Receptors on the NLRP3 Inflammasome Pathway In Vivo.
Sebti Y; Ferri L; Zecchin M; Beauchamp J; Mogilenko D; Staels B; Duez H; Pourcet B
Methods Mol Biol; 2019; 1951():189-207. PubMed ID: 30825154
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 17A plays a role in lipopolysaccharide/D-galactosamine-induced fulminant hepatic injury in mice.
Furuya S; Kono H; Hara M; Hirayama K; Sun C; Fujii H
J Surg Res; 2015 Dec; 199(2):487-93. PubMed ID: 26141869
[TBL] [Abstract][Full Text] [Related]
14. AMSC-derived exosomes alleviate lipopolysaccharide/d-galactosamine-induced acute liver failure by miR-17-mediated reduction of TXNIP/NLRP3 inflammasome activation in macrophages.
Liu Y; Lou G; Li A; Zhang T; Qi J; Ye D; Zheng M; Chen Z
EBioMedicine; 2018 Oct; 36():140-150. PubMed ID: 30197023
[TBL] [Abstract][Full Text] [Related]
15. Protective Role of Shiitake Mushroom-Derived Exosome-Like Nanoparticles in D-Galactosamine and Lipopolysaccharide-Induced Acute Liver Injury in Mice.
Liu B; Lu Y; Chen X; Muthuraj PG; Li X; Pattabiraman M; Zempleni J; Kachman SD; Natarajan SK; Yu J
Nutrients; 2020 Feb; 12(2):. PubMed ID: 32069862
[TBL] [Abstract][Full Text] [Related]
16. Maresin 1 protects against lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting macrophage pyroptosis and inflammatory response.
Yang W; Tao K; Zhang P; Chen X; Sun X; Li R
Biochem Pharmacol; 2022 Jan; 195():114863. PubMed ID: 34861244
[TBL] [Abstract][Full Text] [Related]
17. Pterostilbene Protects Against Lipopolysaccharide/D-Galactosamine-Induced Acute Liver Failure by Upregulating the Nrf2 Pathway and Inhibiting NF-
Zhang E; Huang J; Wang K; Yu Q; Zhu C; Ren H
J Med Food; 2020 Sep; 23(9):952-960. PubMed ID: 32701014
[TBL] [Abstract][Full Text] [Related]
18. Amygdalin attenuates acute liver injury induced by D-galactosamine and lipopolysaccharide by regulating the NLRP3, NF-κB and Nrf2/NQO1 signalling pathways.
Tang F; Fan K; Wang K; Bian C
Biomed Pharmacother; 2019 Mar; 111():527-536. PubMed ID: 30597306
[TBL] [Abstract][Full Text] [Related]
19. Geraniol ameliorates acute liver failure induced by lipopolysaccharide/D-galactosamine via regulating macrophage polarization and NLRP3 inflammasome activation by PPAR-γ methylation Geraniol alleviates acute liver failure.
Ma J; Xu Y; Zhang M; Li Y
Biochem Pharmacol; 2023 Apr; 210():115467. PubMed ID: 36849063
[TBL] [Abstract][Full Text] [Related]
20. Oridonin alleviates d-GalN/LPS-induced acute liver injury by inhibiting NLRP3 inflammasome.
Zhang T; Chen Y; Zhan Z; Mao Z; Wen Y; Liu S; Tang L
Drug Dev Res; 2021 Jun; 82(4):575-580. PubMed ID: 33377532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
